Side-by-side · Research reference

5-Amino-1MQvsCJC-1295 (no DAC)

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AAnimal-StrongDraft8/38 cited

BPhase 1Reviewed15/51 cited

5-Amino-1MQ

NNMT inhibitor · Methylation / SAM modulation

100–200 mgDaily dose (oral)Neelakantan 2018

AnimalEvidence levelNeelakantan 2018

HoursHalf-life (est)

Oral · Once daily fasted

CJC-1295 (no DAC)

Short-acting GHRH · No DAC variant

100 mcgPer doseTeichman 2006

~30 minHalf-lifeIonescu 2006

Phase 1Evidence levelTeichman 2006 Sigalos 2018

SQ · Pre-sleep · 1–2×/day

01Mechanism of Action

Parameter

5-Amino-1MQ

CJC-1295 (no DAC)

Primary target

Nicotinamide N-methyltransferase (NNMT)Neelakantan 2018

Pituitary GHRH receptorTeichman 2006

Pathway

NNMT inhibition → preserved cellular SAM + NAD⁺ → restored methylation balance + ↑ thermogenic gene expressionNeelakantan 2018

GHRH-R → Gαs → cAMP → PKA → GH vesicle exocytosisTeichman 2006

Downstream effect

Reversal of HFD-induced obesity in murine models; improved metabolic profileNeelakantan 2018

Pulsatile GH release matching physiological pattern; subsequent IGF-1 elevationIonescu 2006

Feedback intact?

—

Yes — short pulse preserves somatostatin negative feedbackIonescu 2006

Origin

Selective small-molecule inhibitor designed in academic medicinal chemistry programsNeelakantan 2018

Modified human GRF 1-29 with four substitutions (D-Ala²/Gln⁸/Ala¹⁵/Leu²⁷) for protease resistanceTeichman 2006

Antibody development

—

Not reported in short-term studies

02Dosage Protocols

Parameter

5-Amino-1MQ

CJC-1295 (no DAC)

Standard dose

100–200 mg / day oralNeelakantan 2018

Anecdotal community range; murine doses scaled.

100 mcg per injectionTeichman 2006

Often paired with ipamorelin in same syringe.

Frequency

Once daily, fasted

1–2× daily (pre-sleep ± morning)

Lower / starter dose

50 mg / day

50 mcg per dose

Evidence basis

Animal-strong; no human RCT dataNeelakantan 2018

Phase 1 (CJC-1295 with DAC); analog dataTeichman 2006 Ionescu 2006

No-DAC variant is less studied directly; PK extrapolated from native GHRH.

Duration

8–12 weeks per cycle

8–12 weeks on / 4 off (anecdotal)

Form

Oral capsule

—

Timing

Morning fasted preferred

Pre-sleep + fasted preferred

Half-life

Hours (estimated; no human PK published)

~30 minIonescu 2006

Short pulse vs CJC-1295-DAC (~8 days). Choose no-DAC for pulsatile, DAC for sustained.

Reconstitution

—

Bacteriostatic water

04Side Effects & Safety

Parameter

5-Amino-1MQ

CJC-1295 (no DAC)

GI symptoms

Mild nausea (anecdotal)

—

Methylation disruption

Theoretical risk if NNMT is over-inhibited (B vitamin metabolism)

—

Long-term safety

Unknown — no human trials

—

Cancer risk

Unclear — NNMT also studied in oncology contexts

Contraindicated in active malignancy (GH/IGF-1 axis)

Pregnancy / OB

Avoid

Drug interactions

Theoretical with niacin / B-vitamin supplements

—

Injection site reaction

—

Erythema, mild pruritus

Flushing / headache

—

Common transient effect

Cortisol elevation

—

Minimal at standard doses

Prolactin elevation

—

Minimal

Glucose intolerance

—

Possible at high cumulative doses

IGF-1 elevation

—

Dose-dependent; monitor with chronic use

Absolute Contraindications

5-Amino-1MQ

·Pregnancy / breastfeeding
·Active malignancy

CJC-1295 (no DAC)

·Active malignancy or cancer history
·Pregnancy / breastfeeding
·Disrupted hypothalamic-pituitary axis

Relative Contraindications

5-Amino-1MQ

·Methylation-sensitive conditions (MTHFR mutation)
·Concurrent niacin / NAD+ precursor supplementation (theoretical interference)

CJC-1295 (no DAC)

·Untreated diabetes
·Severe insulin resistance

05Administration Protocol

Parameter

5-Amino-1MQ

CJC-1295 (no DAC)

1. Form

Oral capsule. No injection.

Add 2 mL bacteriostatic water to 2 mg vial → 1 mg/mL = 100 mcg per 0.1 mL. Roll gently.

2. Administration

Take with water, fasted preferred.

Subcutaneous, abdomen or thigh. Rotate sites.

3. Timing

Morning fasted.

Pre-sleep preferred. Often combined with ipamorelin in the same syringe.

4. Storage

Room temp ≤25 °C, dry place.

Lyophilised: room temp, protected from light. Reconstituted: refrigerate 2–8 °C, use within 30 days.

5. Caveat

Monitor B-vitamin status with chronic use.

29–31G, 4–8 mm insulin syringe.

06Stack Synergy

5-Amino-1MQ

— no documented stacks

CJC-1295 (no DAC)

+ Ipamorelin

Strong

View Ipamorelin →

CJC-1295 (no DAC) and ipamorelin are the canonical "GHRH + GHRP" dual-axis stack at physiological timing. Both peak within 30 min and clear within 2 hours, producing a sharp, high-amplitude GH pulse closely resembling natural physiology. Preferred over the CJC-1295-DAC + ipamorelin stack when pulsatility (vs sustained elevation) is the goal.

CJC-1295 (no DAC): 100 mcg SQ · pre-sleep
Ipamorelin: 200–300 mcg SQ · same injection
Primary benefit: Pulsatile GH stimulation, recovery, body composition

Teichman 2006 Raun 1998